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INTRODUCTION
Patients with aggressive non-Hodgkin’s lymphoma (NHL)
can be cured with various chemotherapy regimens, yet the
cure rates vary according to the pretreatment prognostic vari-
ables. Even though several attempts at devising more effec-
tive regimens, cyclophosphamide, doxorubicin, vincristine,
and prednisone (CHOP) combination chemotherapy, which
showed 44% of complete response rate (CR), 42% of 3-yr
disease free survival (DFS) rate, and 54% of 3-yr overall sur-
vival (OS) rate, is still considered as the best available chemo-
therapeutic regimen for aggressive NHL (1, 2). Although
chemotherapy can cure most patients with a localized disease,
only 30% to 40% of patients with an advanced disease are
cured (1-4). Therefore, the major concern for treating aggres-
sive NHL is still to prolong survival and reduce treatment-
related toxicity.
Etoposide has already been reported as an active agent in
the treatment of aggressive NHL (5, 6). In a first-line therapy,
a phase II study with CHOP plus etoposide regimen showed
93% of response rate and 43 months of median survival (5).
Moreover, various combination regimens including etoposide
are widely used for treating refractory or relapsed lymphomas.
As regards anthracyclines that are effective in treating NHL,
doxorubicin is most commonly used. However, Lambertenghi
et al. (7) reported 59% of CR rate and 67% of 7-yr DFS rate
with CEOP regimen, replacing doxorubicin with epirubicin
(4′ -epidoxorubicin). Previous other studies also have indicated
that epirubicin, a derivative of doxorubicin with a different
configuration of the hydroxyl group at the 4′ position, might
be equally effective with less cardiac and hematologic toxicity
(7-9).
Accordingly, the current phase II study was conducted to
evaluate the response rate, toxicity, and survival of a modified
CHOP regimen (the addition of etoposide and replacement
of doxorubicin with epirubicin) for patients with aggressive
NHL.
MATERIALS AND METHODS
Eligibility criteria
Patients entered onto this study were required to fulfill the
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Phase II Study of Cyclophosphamide, Epirubicin, Vincristine, 
Prednisone, and Etoposide (CEOP-E) for Aggressive Non-Hodgkin’ s
Lymphoma
The main objectives of the current study were to evaluate the efficacy and safety of
a CEOP-E regimen for patients with aggressive non-Hodgkin’s lymphoma (NHL).
Fifty-one consecutive patients with newly diagnosed aggressive NHL were enrolled
in the study. Median age of patients was 57 (range, 18-75) yr old, and male to female
ratio was 1.32:1. Diffuse large B cell lymphoma (68.8%) was the most common his-
tological subtype. Thirty patients (58.8%) had Ann Arbor stage III or IV diseases at
diagnosis. One course of chemotherapy consisted of an intravenous combination
of cyclophosphamide 750 mg/m
2, epirubicin 50 mg/m
2, vincristine 2 mg, etoposide
80 mg/m
2 on day 1 and oral administration of 100 mg prednisone on days 1 to 5
(CEOP-E). A complete response or unconfirmed complete response was achieved
in 31 (63.3%) out of 49 evaluated patients. With a median follow-up of 16.3 months,
26 events including relapse and death were observed. The estimated 2-yr survival
rate for all patients and disease free survival rate for patients achieving complete re-
sponse was 58.9% and 57.1%, respectively. Episodes of febrile neutropenia occurred
in 5 (10.2%) patients. Transient episodes of ECG abnormality (1st degree AV block)
were observed in 2 patients. Accordingly, the CEOP-E regimen produced comparable
results to those of other regimens, including CHOP, in terms of the response rate
and overall survival. The current regimen seemed to minimize the cardiac toxicity
due to an accumulated dose of anthracycline in the treatment of aggressive NHL.
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following eligibility criteria: (1) histologically proven aggres-
sive non-Hodgkin’s lymphoma; (2) age between 15 and 75
yr; (3) Eastern Cooperative Oncology Group Scale performance
status of 3 or less; (4) at least one measurable lesion; (5) ade-
quate function of bone marrow (WBC count ≥4,000/ L
and platelet count≥100,000/ L), liver (serum bilirubin level
≤2.0 mg/dL and serum transaminase level≤two times the
upper limit of normal range, and kidney (serum creatinine
level≤1.5 mg/dL); (6) normal cardiac function; (7) no other
severe medical conditions; (8) no other active malignancy;
and (9) provision of written informed consent.
Patient evaluation
All cases were reviewed by an expert hematopathologist
for diagnostic confirmation and classified according to the
revised European-American classification of lymphoid neo-
plasm system (10). Pretreatment evaluation comprised com-
plete blood cell counts, routine chemistry measurement in-
cluding serum lactate dehydrogenase (LDH), chest and abdo-
minal CT scan, bone marrow examination and other tests
when clinically indicated. The disease stage was determined
using the Ann Arbor criteria, and all patients were evaluated
for the presence of risk factors according to the International
Prognostic Index based on age, stage, performance status,
number of extranodal sites of disease, and LDH (11).
Treatment schedule
One course of chemotherapy consisted of an intravenous
combination of cyclophosphamide 750 mg/m2, epirubicin
50 mg/m2, vincristine 2 mg, and etoposide 80 mg/m2 on day
1 and oral administration of 100 mg prednisone on days 1
to 5 (CEOP-E), which was repeated every 3 weeks. Patients
with a stage I or II disease were planned to receive four courses
of chemotherapy followed by involved-field radiotherapy (30-
40 Gy), while patients with an advanced disease were planned
to receive six courses of chemotherapy followed by radiother-
apy to bulky sites. Chemotherapy was withheld for 1 week
until the neutrophil count was higher than 1.5×103/ L and
the platelet count more than 100×109/L. If febrile neutrope-
nia or grade IV neutropenia occurred, the starting dose of
cyclophosphamide, epirubicin, and etoposide was reduced
by 25% in the subsequent course of treatment. The prophy-
lactic use of a colony-stimulating factor was not permitted.
To evaluate the cardiac toxicity, electrocardiography and chest
radiography were performed before and after every second
course of chemotherapy and 2D echocardiography was con-
ducted when clinically indicated.
Definition of response and toxicity
The patient response was evaluated after three courses of
treatment and 1 month after completion of treatment. In
patients with a stage I or II disease, the response evaluated
after completion of radiotherapy was regarded as a maximal
response. A complete response was defined as the disappear-
ance of all clinical evidence of disease and normalization of
those biochemical abnormalities (e.g. LDH). An unconfirmed
complete response was defined as a residual lymph node mass
with a diameter greater than 1.5 cm after a 75% or more
reduction in the sum of the diameters of all measurable lesions.
A partial response was defined as a 50% or more reduction in
the sum of the diameters of all measurable lesions that per-
sisted for at least 4 weeks, no increase in the size of any pre-
existing lesions, and no new lesions. A stable disease was de-
fined as less than a partial response, yet not progressive. A
progressive disease was defined as 50% or more increase in
the sum of the diameters of any measurable lesions or the
appearance of a new lesion (12). Toxicity was evaluated and
graded according to the National Cancer Institute Common
Toxicity Criteria (NCI CTC) version 2.0 grading system.
Statistical analysis
An optimal, two-stage Simon design was used to determine
the exact number of patients to be accrued in the current trial.
The hypotheses was that H0: P≤P0 (0.30) versus H1: P≥P1
(0.50) with  =0.05, and  =0.20 (80% power). Therefore,
19 patients were enrolled in the first stage of trial and eval-
uated for response. If 7 or more patients showed a CR, then
the study proceeded to the second stage. Allowing for a fol-
low-up loss rate of 10%, the total sample size was 43 patients
with a measurable disease. OS was measured from the study
entry until the date of death or last follow-up and progres-
sion free survival (PFS) was calculated from the study entry
until treatment failure (disease progression, relapse, or death
of any cause). DFS was measured from the date of a complete
response until the date of the first relapse, death, or last fol-
low-up. The efficacy and toxicity was analyzed by per pro-
tocol base. OS curves were plotted using the Kaplan-Meier
method and compared using a log-rank test. The statistical
data were obtained using the SPSS software package (SPSS
10.0 Inc. Chicago, IL, U.S.A.).
RESULTS
Patient characteristics
Fifty-one consecutive patients with newly diagnosed aggres-
sive NHL were enrolled in the study from February 2000 to
November 2002 at Kyungpook National University Hospital
(Daegu, Korea). The patient characteristics are summarized
in Table 1. Diffuse large B cell lymphoma (68.8%) was the
most common histological subtype, while 13 (25.5%) patients
were diagnosed with peripheral T cell lymphomas. Thirty
patients (58.8%) had Ann Arbor stage III or IV diseases at822 J.G. Kim, S.K. Sohn, D.H. Kim, et al.
diagnosis and 17 (33.3%) patients were classified as high-inter-
mediate or high risk according to the International Prognos-
tic Index (IPI) scoring system. The characteristics including
age, stage, bulky disease, and IPI between B cell subtypes
and T cell subtypes were not significantly different.
Response and survival
The responses of two patients were not evaluated due to
follow-up loss, as such, these patients were withdrawn from
the study. Eighteen (85.7%) out of 21 patients with localized
disease completed a planned chemotherapy followed by in-
volved field radiotherapy. A CR or unconfirmed complete
response was achieved in 31 (63.3%) out of 49 patients (Table
2). With a median follow-up of 16.3 months, 26 events (10
relapses or 16 deaths) were observed. Fifteen out of 16 deaths
were due to disease progression, and 1 patient died of febrile
neutropenia and pneumonia. Estimated 2-yr survival rate
and PFS rate for all patients was 58.9% and 43.8%, respec-
tively (Fig. 1A, B). DFS rate for patients achieving a complete
response was 57.1% (Fig. 1C). A statistically significant dif-
ference in the PFS rate was observed among the subgroups
according to the IPI (estimated 2-yr PFS rate for low, low-
intermediate, high-intermediate, and high risk groups was
59.9%, 51.5%, 16.7%, and 0%, respectively, p=0.0043) (Fig.
2). Estimated 2-yr OS rate was not statistically different be-
tween for patients with B cell NHL and with T cell NHL
(66.0% vs. 58.7%, p=0.1840) (Fig. 3).
Toxicity
A total of 229 courses of chemotherapy were administrated
to 49 patients. Thirty-six (73.5%) of the 49 patients complet-
ed the planned treatment schedule. Treatment delays were
observed in 12 (24.5%) patients due to neutropenia or throm-
bocytopenia. A dose reduction was required in 10 (20.4%)
patients. The median dose intensity for the cyclophosphamide,
epirubicin, vincristine, and etoposide over all treatment cycles
was 221.8 mg/m2/week, 14.8 mg/m2/week, 6.6 mg/m2/week,
and 23.4 mg/m2/week, corresponding to 88.7%, 88.7%, 98.2
%, and 87.6% of the planned dose intensities, respectively. 
NCI CTC grade III or IV neutropenia occurred in 6 (12.2%)
patients, and episodes of grade III or IV febrile neutropenia
was observed in 5 (10.2%) patients (Table 3). Nausea and
stomatitis were the most common non-hematological toxic-
ities. Grade 1/2 nausea and stomatitis was observed in 34.7%
and 36.7% of patients, respectively (Table 3). Transient epi-
sodes of ECG abnormality (1st degree AV block) were observed
in two patients, yet they showed normal ejection fraction in
2D echocardiography. Secondary leukemia or myelodysplastic
syndrome induced by etoposide or other chemotherapeutic
agents was not observed.
Patient profile No. (%)
Age, median (range) (yr) 57 (18-75)
Sex
Male 29 (56.9)
Female 22 (43.1)
ECOG performance status
0-1 45 (88.2)
2-3 6 (11.8)
Histology
Diffuse large B cell 35 (68.8)
Extranodal marginal zone B cell 2 (3.9)
Mantle cell 1 (2.0)
Peripheral T cell, unspecified 6 (11.8)
Angiocentric 5  (9.8)
Anaplastic large cell 1 (2.0)
Angioimmunoblastic T-cell 1 (2.0)
B symptoms 10 (19.6)
Stage (Ann Arbor)
I 10 (19.6)
II 11 (21.6)
III 19 (37.3)
IV 11 (21.6)
Bulky disease (≥10 cm) 12 (23.5)
International Prognostic Index
Low 0-1 22 (43.2)
Low-intermediate 2 12 (23.5)
High-intermediate 3 14 (27.5)
High 4-5 3 (5.9)
Table 1. Patient characteristics
Response No. (%)
Complete response 29 (59.8)
Unconfirmed complete response 2 (4.1)
Partial response 9 (18.4)
Stable disease 6 (12.2)
Progressive disease 3 (6.1)
Table 2. Response to treatment
NCI-CTC grade: No. (%) of patients (n=49)
Grade 1 Grade 2 Grade 3 Grade 4
Hematologic
Anemia 14 (28.6) 4 (8.2)
Leukopenia 14 (28.6) 7 (14.3) 3 (6.1) 2 (4.1)
Neutropenia 15 (30.6) 6 (12.2) 4 (8.2) 2 (4.1)
Thrombocytopenia 4 (8.2) 3 (6.1) 1 (2.0)
Non-hematologic
Nausea 12 (24.5) 5 (10.2)
Stomatitis 13 (26.5) 5 (10.2) 2 (4.1)
Diarrhea 5 (10.2) 2 (4.1)
Constipation 9 (18.4) 3 (6.1) 1 (2.0)
Neuropathy 4 (8.2) 3 (6.1) 1 (2.0)
Febrile neutropenia 4 (8.2) 1 (2.0)
Infection  4 (8.2) 2 (4.1)
without neutropenia
Table 3. Adverse reactionsCEOP-E Therapy for Non-Hodgkin’s Lymphoma 823
DISCUSSION
The main objectives of the current study were to improve
the response rate with a modified CHOP regimen including
etoposide and reduce the toxicity associated with anthracy-
clines in the treatment of patients with aggressive NHL. As
a result, a complete response was observed in 63.3% of the
patients, while estimated 2-yr OS and DFS rate was 58.9%
and 57.1%, respectively. These results are similar to those
recorded in previous trials using a CHOP regimen for patients
with aggressive NHL, where the complete response rates
ranged from 44-74% and estimated 2 or 3-yr DFS rate ranged
from 44-64% (2, 13-15). A subgroup analysis of the current
series revealed that patients in the high-intermediate and high-
risk groups with respect to the IPI scoring system had an OS
rate of 43.2%, whereas patients in the low and low-intermedi-
ate risk groups had an OS rate of 67.8% after 2 yr (Fig. 2A).
Fig. 1. Survival curves. (A) Estimated 2-yr overall survival rate and
(B) DFS rate for all patients was 58.9% and 43.8%, respectively.
(C) Disease-free survival rate for patients that achieved complete
response was 57.1%.
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Fig. 3. Survival curves according to immunophenotype. Estimated
two-year survival rate was statistically not different between for pa-
tients with B cell NHL and for patients with T cell NHL (66.0% vs.
58.7%, p=0.1840).
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Fig. 2. Survival curves according to International Prognostic Index.
Estimated 2-yr PFS rate for low, low-intermediate, high-intermediate,
and high risk groups was 59.9%, 51.5%, 16.7%, and 0%, respec-
tively (p=0.0043).824 J.G. Kim, S.K. Sohn, D.H. Kim, et al.
These results are comparable to those of the International NHL
Prognostic Factors Project (11) that included 3,273 patients
with aggressive NHL.
The current study included a relatively large proportion
(25.5%) of peripheral T cell lymphomas, which are known
to have a poorer prognosis than B cell lymphomas (16, 17).
Nonetheless, the OS rate for patients with peripheral T cell
lymphomas was not statistically different from that for pati-
ents with B cell lymphomas (Fig. 3). Previous studies on CH-
OP plus etoposide regimens have also reported on improved
treatment results for various subtypes of NHL (5, 6, 18). Ka-
rakas et al. (6) found that peripheral T-cell lymphomas res-
ponded well to a CHOP plus etoposide regimen with a similar
outcome to high-grade B-cell lymphomas. Therefore, given
these results, it was postulated that the addition of etoposide
to a CEOP regimen could improve the outcome of peripheral
T cell lymphomas.
The administration of doxorubicin in the treatment of NHL
has occasionally exhibited limitations due to dose-related con-
gestive cardiomyopathy. Haddy et al. (19) reported that left
ventricular dysfunction as a significant late toxic event in long-
term survivors of high-grade NHL was identified in eight
(14.0%) of 57 patients who received more than 200 mg/m2
of doxorubicin. Miller et al. (15) also have observed left ven-
tricular dysfunction in 1.5% of patients treated after eight
cycles of CHOP. Cardiac toxicity is more problematic in a
relapsed setting, since relapsed patients are mostly exposed to
additional anthracyclines or higher doses of other cardiotoxic
agents for salvage therapy or high-dose chemotherapy with
stem cell support. As such, less cardiotoxic, yet equally effi-
cacious, anthracycline agent is preferred as a frontline drug
for NHL. Epirubicin in combination with other chemother-
apeutic agents exhibited 58.3-90% of CR rates and 61.8-63.5
% of 5-yr DFS rate in the previous studies (20-22), which
were similar therapeutic activity to doxorubicin in combina-
tion with other agents. However, epirubicin has a more favor-
able adverse effect profile with lower hematologic toxicity,
mucositis, and cardiac toxicity (23). In the current study, febrile
neutropenia was observed in 10.2% of patients, while grade
III or IV neutropenia was only observed in 12.2% of patients,
despite the addition of etoposide to a CEOP regimen. Plus,
no clinically significant cardiac event was recorded. Thus, car-
diac morbidity due to salvage regimens or high-dose chemo-
therapy with stem cell support may be minimized in relaps-
ing patients who have been treated with a regimen including
epirubicin.
In Coiffier et al.’s study (24) on the addition of rituximab to
a CHOP regimen, which improved survival in elderly patients
with diffuse large B cell lymphomas, grade III or IV cardiac
toxicity was observed in 8% of patients. Therefore, especially
for elderly patients with NHL, epirubicin may be more appro-
priate than doxorubicin as the anthracycline component of
the first-line regimen. Furthermore, clinical trials using rit-
uximab plus a CEOP or CEOP+E regimen to reduce the tox-
icities in elderly patients can be planned.
In conclusion, the CEOP-E regimen was found to be com-
parable to other regimens, including CHOP, in terms of the
response rate and overall survival, and seemed to apparently
minimize the cardiac toxicity due to an accumulated dose of
anthracycline in the treatment of aggressive NHL.
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